Skip to main content

Advertisement

SpringerLink
Log in

Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of

  • Brief Report
  • Published:
Journal of Nuclear Cardiology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol. 2009;54:1123–30.

    Article  CAS  PubMed  Google Scholar 

  2. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nuclear Cardiol. 2007;14:645–58.

    Article  Google Scholar 

  3. Pandit A, Unzek Freiman S. Complete heart block associated with regadenoson: A real side effect. J Nuclear Cardiol. 2012;19:1236–9.

    Article  Google Scholar 

  4. Rosenblatt J, Mooney D, Dunn T, Cohen M. Asystole following regadenoson infusion in stable outpatients. J Nuclear Cardiol. 2014;21:862–8.

    Article  Google Scholar 

  5. Agarwal V, DePuey EG. Advanced heart block and unresponsiveness after regadenoson administration during myocardial SPECT study. Int. J Nuclear Cardiol. 2014;176:e49–51.

    Article  Google Scholar 

  6. Grady EC, Barron JT, Wagner RH. Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine. J Nuclear Cardiol. 2011;18:521–5.

    Article  Google Scholar 

  7. Brinkert M, Reyes E, Walker S, Latus K, Maenhout A, Mizumoto R, et al. Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy. Eur J Nucl Med Mol Imaging. 2014;41:511–21.

    Article  CAS  PubMed  Google Scholar 

  8. U.S. Food and Drug Administration. OpenFDA. https://openfda.shinyapps.io/dash/; 2016.

  9. Garnock-Jones KP, Curran MP. Regadenoson. Am J Cardiovasc Drugs. 2012;10:65–71.

    Article  Google Scholar 

  10. Zoghbi GJMD, Iskandrian AEMD. Selective adenosine agonists and myocardial perfusion imaging. J Nuclear Cardiol. 2012;19:126–41.

    Article  Google Scholar 

  11. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nuclear Cardiol. 2012;19:681–92.

    Article  Google Scholar 

  12. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008;1:307–16.

    Article  PubMed  Google Scholar 

  13. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet. 2006;45:1201–12.

    Article  CAS  PubMed  Google Scholar 

  14. Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation. J Nuclear Cardiol. 2012;20:205–13.

    Article  Google Scholar 

  15. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47:825–33.

    Article  CAS  PubMed  Google Scholar 

  16. Myers J, Arena R, Franklin B, Pina I, Kraus WE, McInnis K, et al. Recommendations for Clinical Exercise Laboratories. A Sci Statement Am Heart Assoc. 2009;119:3144–61.

    Google Scholar 

  17. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nuclear Cardiol. 2016;23:606–39.

    Article  Google Scholar 

  18. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nuclear Cardiol. 2016;23:1187–226.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA

    Faraz Kureshi MD, MSc & Timothy M. Bateman MD

  2. University of Missouri- Kansas City, Kansas City, MO, USA

    Faraz Kureshi MD, MSc & Timothy M. Bateman MD

  3. Cleveland Clinic, Cleveland, OH, USA

    Mouin S. Abdallah MD, MSc

Authors
  1. Faraz Kureshi MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mouin S. Abdallah MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy M. Bateman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faraz Kureshi MD, MSc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kureshi, F., Abdallah, M.S. & Bateman, T.M. Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of. J. Nucl. Cardiol. 24, 2019–2024 (2017). https://doi.org/10.1007/s12350-016-0755-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-016-0755-1

Search

Navigation